Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2a open-label dose-escalation study of GS030 in retinitis pigmentosa
2024-516059-42-00Phase 2Authorised
- Sponsor
- GenSight Biologics
- Start
- Aug 2024
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 3
01
Overview
Phase 2, open-label, single-arm trial of GS030 in retinitis pigmentosa (RP), sponsored by GenSight Biologics. Planned start Aug 2024; status: authorised.
02
Drugs
GS030
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on 2024-516059-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516059-42-00.